Transplantation of kidneys from donors with hepatitis C antibody into recipients with pre-transplantation anti-HCV

Kidney Int. 1995 Jan;47(1):236-40. doi: 10.1038/ki.1995.29.

Abstract

Hepatitis C virus (HCV) is transmitted by organ transplantation. Consequently, several organ procurement organizations have imposed a moratorium on use of organs from anti-HCV positive donors. Because of the inadequate supply of cadaver kidneys for transplantation, we adopted a policy to transplant kidneys from anti-HCV donors into anti-HCV positive recipients. During the period between March 1990 and December 1992, 24 anti-HCV positive dialysis patients received a kidney from anti-HCV positive donors (group I) and 40 anti-HCV positive patients received a kidney from anti-HCV negative donors (group II). We compared the prevalence of liver disease, anti-HCV, HCV RNA, graft and patient survival between groups. Pre-transplantation 17 of 24 (71%) patients in group I and 31 of 40 (79%) of patients in group II had serum HCV RNA. Post-transplantation follow-up was 26 +/- 8 months and 30 +/- 10 months in groups I and II, respectively. During follow-up, elevated ALT levels were present in 7 of 24 (29%) and 16 of 40 (40%) of patients in groups I and II, respectively (P > 0.05). Post-transplantation, all patients in both groups retained anti-HCV. The prevalence of HCV RNA post-transplantation was 22 of 23 (96%) patients in group I and 30 of 39 (77%) of patients in group II (P > 0.05). Graft and patient survival in group I (96% and 100%, respectively) were not significantly different from those in group II (93% and 98%, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Female
  • Graft Survival
  • Hepacivirus / immunology*
  • Hepacivirus / isolation & purification
  • Hepatitis Antibodies / immunology*
  • Hepatitis C / immunology*
  • Hepatitis C / surgery
  • Hepatitis C Antibodies
  • Humans
  • Kidney / immunology
  • Kidney Transplantation / immunology*
  • Male
  • Middle Aged
  • Prevalence
  • RNA, Viral / analysis
  • Survival Analysis
  • Tissue Donors*

Substances

  • Hepatitis Antibodies
  • Hepatitis C Antibodies
  • RNA, Viral